|
|
|
Many Roles of CCL20: Emphasis on Breast Cancer
|
|
|
|
|
|
|
|
|
|
|
|
|
Kingsley O. Osuala and Bonnie F. Sloane
|
|
|
|
Wayne State University
|
Department of Pharmacology, Wayne State University, School of Medicine, Detroit, MI 48201, USA
|
|
kosuala@med.wayne.edu
|
|
|
|
|
|
|
|
|
|
|
CCL20 or MIP3[alpha] is a small ~8 kDa protein primarily expressed in the liver, colon, prostate, cervix, and skin. The cellular receptor for CCL20 is CCR6. CCl20 unlike many other cytokines only binds CCR6, making the CCL20/CCR6 pathway an attractive drug target. Since the initial discovery of CCL20 in the early 1990's, there has been an increase in the evidence implicating the chemokine and its receptor in a number of diseases, including rheumatoid arthritis and human immunodeficiency virus infection. CCL20 has also been linked to malignancies such as ovarian, colorectal and pancreatic cancers. CCL20 can also attract tumor-promoting immune-suppressive cells to the tumor microenvironment, which may contribute to the immune evasive potential of the tumor and tumor progression.
|
|
|
|
|
|
|
|
|
|